A detailed history of Price T Rowe Associates Inc transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 71,136 shares of ARWR stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
71,136
Previous 60,568 17.45%
Holding current value
$1.79 Million
Previous $1.85 Million 9.76%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$27.21 - $39.48 $287,555 - $417,224
10,568 Added 17.45%
71,136 $2.04 Million
Q4 2023

Feb 14, 2024

BUY
$21.2 - $31.03 $211,576 - $309,679
9,980 Added 19.73%
60,568 $1.85 Million
Q3 2023

Nov 14, 2023

SELL
$26.2 - $36.08 $108,415 - $149,299
-4,138 Reduced 7.56%
50,588 $1.36 Million
Q2 2023

Aug 14, 2023

BUY
$25.16 - $41.38 $68,082 - $111,974
2,706 Added 5.2%
54,726 $1.95 Million
Q1 2023

May 15, 2023

BUY
$23.68 - $38.51 $29,836 - $48,522
1,260 Added 2.48%
52,020 $1.32 Million
Q4 2022

Feb 14, 2023

SELL
$28.0 - $40.56 $3,416 - $4,948
-122 Reduced 0.24%
50,760 $2.06 Million
Q3 2022

Nov 14, 2022

BUY
$29.63 - $48.31 $139,142 - $226,863
4,696 Added 10.17%
50,882 $1.68 Million
Q2 2022

Aug 15, 2022

SELL
$27.79 - $50.61 $71,003 - $129,308
-2,555 Reduced 5.24%
46,186 $1.63 Million
Q1 2022

May 16, 2022

BUY
$39.62 - $69.97 $161,808 - $285,757
4,084 Added 9.15%
48,741 $2.24 Million
Q4 2021

Feb 14, 2022

SELL
$58.09 - $82.51 $174,850 - $248,355
-3,010 Reduced 6.31%
44,657 $2.96 Million
Q3 2021

Nov 15, 2021

BUY
$58.38 - $84.96 $7,472 - $10,874
128 Added 0.27%
47,667 $2.98 Million
Q2 2021

Aug 16, 2021

SELL
$62.15 - $90.32 $214,914 - $312,326
-3,458 Reduced 6.78%
47,539 $3.94 Million
Q1 2021

May 17, 2021

SELL
$61.35 - $90.47 $274,234 - $404,400
-4,470 Reduced 8.06%
50,997 $3.38 Million
Q4 2020

Feb 16, 2021

BUY
$43.82 - $85.37 $2.43 Million - $4.74 Million
55,467 New
55,467 $4.26 Million

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.67B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.